FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting

The Committee discusses and makes recommendations on the safety and effectiveness of GSK‘s Biologics License Application (BLA) 125775 (STN 125775/o) for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older in a virtual meeting to be held on March 1 at 8 am. Webcast Link